The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis

British Journal of Haematology

Volumn 161, Issue 3, 2013, Pages 367-372

  Dinner, Shira ^a   Witteles, Wesley ^b   Witteles, Ronald ^a   Lam, Anthony ^a   Arai, Sally ^a   Lafayette, Richard ^a   George, Tracy I ^a   Schrier, Stanley L ^a   Liedtke, Michaela ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

Amyloidosis; Immunohistochemistry; Morphology; Multiple myeloma

Indexed keywords

ANTHRACYCLINE; BORTEZOMIB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN LIGHT CHAIN; LENALIDOMIDE; M PROTEIN; MELPHALAN; SYNDECAN 1;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CLINICAL ARTICLE; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PLASMA CELL; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL;

ADRENAL CORTEX HORMONES; AGED; AGED, 80 AND OVER; AMYLOIDOSIS; ANTINEOPLASTIC AGENTS; BONE MARROW; BONE MARROW EXAMINATION; CARDIOMYOPATHIES; CELL COUNT; CLONE CELLS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MYELOMA PROTEINS; MYOCARDIUM; PHENOTYPE; PLASMA CELLS; PROGNOSIS; SYNDECAN-1; VISCERA;

EID: 84876160741     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12269     Document Type: Article

References (17)

1. Comenzo, R.L. (2009) How I treat amyloidosis. Blood, 114, 3147-3157.
2. Dimopoulos, M., Kyle, R., Fermand, J.P., Rajkumar, S.V., Miguel, J.S., Chanan-Khan, A., Ludwig, H., Joshua, D., Mehta, J., Gertz, M., Avet-Loiseau, H., Beksac, M., Anderson, K., Moreau, P., Singhal, S., Goldschmidt, H., Boccadoro, M., Kumar, S., Giralt, S., Munshi, N. & Jagannath, S. (2011) Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood, 117, 4701-4705.
3. Dispenzieri, A., Gertz, M. & Buadi, F. (2012) What do I need to know about immunoglobulin light chain (AL) amyloidosis? Blood Reviews, 26, 137-154.
4. Gertz, M.A., Kyle, R.A. & Greipp, P.R. (1991) Response rates and survival in primary systemic amyloidosis. Blood, 77, 257-262.
5. Gertz, M.A., Lacy, M.Q. & Dispenzieri, A. (1999) Amyloidosis. Hematology Oncology Clinics of North America, 13, 1211-1233.
6. Gertz, M.A., Comenzo, R., Falk, R., Hazenberg, B.P., Hawkins, P.N., Merlini, G., Moreau, P., Ronco, P., Sanchorawala, V., Sezer, O., Solomon, A. & Grateau, G. (2005) Definition of organ involvement and treatment response in immunoglobulin light Chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. American Journal of Hematology, 79, 319-328.
7. Hoffman, J., Jhanwar, S. & Comenzo, R.L. (2009) AL amyloidosis and progression to multiple myeloma with gain(1q). British Journal of Haematology, 144, 963-964.
8. International Myeloma Working Group (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. British Journal of Haematology, 121, 749-757.
9. Kumar, S.K., Rajkumar, S.V., Dispenzieri, A., Lacy, M.Q., Hayman, S.R., Buadi, F.K., Zeldenrust, S.R., Dingli, D., Russell, S.J., Lust, J.A., Greipp, P.R., Kyle, R.A. & Gertz, M.A. (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood, 111, 2516-2520.
10. Kumar, S., Dispenzieri, A., Katzmann, J., Larson, D.R., Colby, C.L., Lacy, M.Q., Hayman, S.R., Buadi, F.K., Leung, N., Zeldenrust, S.R., Ramirez-Alvarado, M., Clark, R.J., Kyle, R.A., Rajkumar, S.V. & Gertz, M.A. (2010) Serum immunoglobulin free light chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood, 116, 5126-5129.
11. Kumar, S., Dispenzieri, A., Lacy, M.Q., Hayman, S.R., Buadi, F.K., Colby, C., Laumann, K., Zeldenrust, S.R., Leung, N., Dingli, D., Greipp, P.R., Lust, J.A., Russell, S.J., Kyle, R.A., Rajkumar, S.V. & Gertz, M.A. (2012) Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. Journal of Clinical Oncology, 30, 989-995.
12. Kyle, R.A. & Gertz, M.A. (1995) Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Seminars in Hematology, 32, 45-59.
13. Kyle, R.A. & Greipp, P.R. (1983) Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clinic Proceedings, 58, 665-683.
14. Paiva, B., Vidriales, M.B., Perez, J.J., López-Berges, M.C., García-Sanz, R., Ocio, E.M., de Las Heras, N., Cuello, R., García de Coca, A., Pardal, E., Alonso, J., Sierra, M., Bárez, A., Hernández, J., Suárez, L., Galende, J., Mateos, M.V. & San Miguel, J.F. (2011) The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis. Blood, 117, 3613-3616.
15. Pardanani, A., Witzig, T.E., Schroeder, G., McElroy, E.A., Fonseca, R., Dispenzieri, A., Lacy, M.Q., Lust, J.A., Kyle, R.A., Greipp, P.R., Gertz, M.A. & Rajkumar, S.V. (2003) Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. Blood, 101, 827-830.
16. Perfetti, V., Colli Vignarelli, M., Anesi, E., Garini, P., Quaglini, S., Ascari, E. & Merlini, G. (1999) The degrees of plasma cell clonality and marrow infiltration adversely influence the prognosis of AL amyloidosis patients. Haematologica, 84, 218-221.
17. Rajkumar, S.V., Gertz, M.A. & Kyle, R.A. (1998) Primary systemic amyloidosis with delayed progression to multiple myeloma. Cancer, 82, 1501-1505.